Alembic Pharmaceuticals Limited has officially confirmed the appointment of Mr. Chirayu Amin as Executive Chairman, effective April 1, 2026. The company has formally notified stock exchanges BSE and NSE about this leadership transition through regulatory filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details and Regulatory Compliance

The appointment follows comprehensive shareholder approval obtained during the company's 15th Annual General Meeting held on August 5, 2025. The company has fulfilled all regulatory requirements and submitted the necessary documentation to both BSE and NSE.

Leadership Transition and Role Change

Mr. Chirayu Amin has relinquished his position as Chief Executive Officer upon completion of his former tenure as Chairman & CEO on March 31, 2026. This strategic transition maintains leadership continuity while restructuring executive responsibilities.

The company has confirmed that Mr. Amin is not debarred from holding the office of Director by virtue of any SEBI order or any other regulatory authority. All AGM proceedings were submitted to stock exchanges on August 5, 2025, ensuring complete transparency.

Professional Background and Company Impact

Mr. Amin brings substantial educational credentials to his role, holding a bachelor's degree in science from Maharaja Sayajirao University of Baroda and a master's degree in business administration from Seton Hall University, New Jersey, USA.

Under his leadership, management and guidance, the company has witnessed exceptional growth. He has played a pivotal role in steering the company towards sustained growth and innovation, with his continued association expected to be valuable for long-term success.

Social Initiatives and Family Connections

Beyond corporate responsibilities, Mr. Amin maintains active involvement in philanthropic initiatives as trustee with Bhailal Amin General Hospital, Uday Education Society, and Bal Utkarsh Society. Through these trusts, he has contributed significantly to initiatives improving access to quality healthcare, supporting educational institutions, and promoting social welfare.

The appointment maintains family involvement in leadership structure, as Mr. Chirayu Amin is the father of Mr. Pranav Amin and Mr. Shaunak Amin, who serve as Managing Directors of Alembic Pharmaceuticals. This relationship has been disclosed in accordance with corporate governance requirements.

Alembic Pharmaceuticals has officially announced the re-appointment of Mr. Pranav Amin as Managing Director for a five-year term, effective from April 1, 2026. The appointment follows shareholder approval obtained during the company's 15th Annual General Meeting held on August 5, 2025.

Leadership Continuity and Governance

The re-appointment ensures leadership continuity at Alembic Pharmaceuticals, with Mr. Pranav Amin continuing in his role as Managing Director. The position is designated as not liable to retire by rotation, providing stability to the company's executive leadership structure.

Professional Background and Role

Mr. Pranav Amin currently heads the International Business division of Alembic Pharmaceuticals. According to the company's disclosure, he has been instrumental in driving growth in the pharmaceutical sector with a strong vision for innovation and global expansion. Under his leadership, the company has strengthened its presence in international markets while focusing on research, development, and high-quality manufacturing.

The company reports that it has experienced remarkable progress under his guidance, achieving sustained growth in both revenue and profitability. His role encompasses overseeing the company's international operations and strategic expansion initiatives.

Family Connections and Board Structure

The disclosure reveals family relationships within the company's leadership structure. Mr. Chirayu Amin, who serves as Chairman of Alembic Pharmaceuticals, is the father of Mr. Pranav Amin. Additionally, Mr. Shaunak Amin, another Managing Director of the company, is also part of the family leadership team.

Regulatory Compliance

Alembic Pharmaceuticals has confirmed full regulatory compliance regarding the appointment. The company has declared that Mr. Pranav Amin is not debarred from holding the office of Director by virtue of any SEBI order or any other regulatory authority. All required details have been submitted in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

The appointment represents continuity in the company's leadership structure and reinforces its commitment to sustained growth in both domestic and international pharmaceutical markets.